secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001787306-25-000091
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q1 product revenue $63.8M (+196% YoY); net loss narrows; appoints new CFO
--------------------------------------------------------------------------------

- Net product revenue $63.8M, up 196% YoY; down 2% QoQ due to deductible resets.
- Net loss $25.1M ($0.20/shr) vs $35.4M ($0.32/shr) YoY improvement.
- Latha Vairavan appointed CFO effective May 6, 2025.
- Patent litigation against Padagis stayed; all deadlines cancelled; 30-month extension.
- PDUFA May 22 for ZORYVE foam 0.3% for scalp/body psoriasis; sNDA for cream 0.05% with PDUFA Oct 13.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/0001787306-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/arqt-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer